Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (851-860 of 1,482) with videos related to

Pageof 149
Sort By:
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|April 11, 2019
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaDaniel A Pollyea, Martin S Tallman, Stéphane de Botton, et al.
Blood Cancer Journal|January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapySangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
Journal of Hematology & Oncology|November 16, 2024
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosisSamuel Urrutia, Hagop M Kantarjian, Farhad Ravandi-Kashani, et al.
Plos Genetics|July 25, 2024
Maternal regulation of the vertebrate oocyte-to-embryo transitionRicardo Fuentes, Florence L Marlow, Elliott W Abrams, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End ResultsKoji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
Blood Advances|November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemiaNicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.
Transfusion|January 25, 2021
Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testingAlfredo Mendrone-Junior, Carla Luana Dinardo, Suzete Cleuza Ferreira, et al.
Leukemia & Lymphoma|August 12, 2021
Clinical and molecular characterization of myeloid sarcoma without medullary leukemiaHussein A Abbas, Patrick K Reville, Alexis Geppner, et al.
Pageof 149

Showing results (851-860 of 1,482) with videos related to

Sort By:
Pageof 149
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|April 11, 2019
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaDaniel A Pollyea, Martin S Tallman, Stéphane de Botton, et al.
Blood Cancer Journal|January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapySangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
Journal of Hematology & Oncology|November 16, 2024
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosisSamuel Urrutia, Hagop M Kantarjian, Farhad Ravandi-Kashani, et al.
Plos Genetics|July 25, 2024
Maternal regulation of the vertebrate oocyte-to-embryo transitionRicardo Fuentes, Florence L Marlow, Elliott W Abrams, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End ResultsKoji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
Blood Advances|November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemiaNicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.
Transfusion|January 25, 2021
Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testingAlfredo Mendrone-Junior, Carla Luana Dinardo, Suzete Cleuza Ferreira, et al.
Leukemia & Lymphoma|August 12, 2021
Clinical and molecular characterization of myeloid sarcoma without medullary leukemiaHussein A Abbas, Patrick K Reville, Alexis Geppner, et al.
Pageof 149